A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published in the 12 February 2015 issue of the Journal Cell [I.F:33] by Drs. Alberto Mantovani , Eduardo Bonavita and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Angiotensin II inhibitors as Anticancer agents: Angiotensin II suppresses the expression of oncogenic suppressor PTX3 and promotes complement-dependent inflammation via up regulation of its target gene. This study suggests, for the first time, Angiotensin II, by inducing the expression of its target gene, it may: (1) suppress the expression of PTX3; (2) complement-dependent tumor inflammation, and (3) tumorigenesis. Angiotensin II inhibitors have long been used to inhibit hypertension, diabetic nephropathy and congestive heart failure. However, this study suggests, for the first time, that angiotensin II inhibitors can function as Anticancer agents. Because of its anti-hypertensive, and anti-diabetic qualities, the angiotensin II inhibitors have an added advantage to be used as anti-cancer agents. Together, pharmacological formulations encompassing ” Angiotensin II inhibitors” may be used to treat patients suffering from inflammation-associated tumorigenesis.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Angiotensin II inhibitors as Anticancer agents: Angiotensin II suppresses the expression of oncogenic suppressor PTX3 and promotes complement-dependent inflammation via up regulation of its target gene, 2/March/2015, 13.55, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Angiotensin II suppresses the expression of PTX3
Amount: $500*